Download PDF
J Knee Surg 2022; 35(08): 909-915
DOI: 10.1055/s-0040-1721092
Original Article

Discontinued Use of Outpatient Portable Intermittent Pneumatic Compression Devices May Be Safe for Venous Thromboembolism Prophylaxis in Primary Total Knee Arthroplasty Using Low-Dose Aspirin

Alex Tang 
1   Department of Orthopedic Surgery, NYU Langone Health, New York, New York
,
Stephen Zak
1   Department of Orthopedic Surgery, NYU Langone Health, New York, New York
,
Katherine Lygrisse
1   Department of Orthopedic Surgery, NYU Langone Health, New York, New York
,
James Slover
1   Department of Orthopedic Surgery, NYU Langone Health, New York, New York
,
Morteza Meftah
1   Department of Orthopedic Surgery, NYU Langone Health, New York, New York
,
Claudette Lajam
1   Department of Orthopedic Surgery, NYU Langone Health, New York, New York
,
Ran Schwarzkopf
1   Department of Orthopedic Surgery, NYU Langone Health, New York, New York
,
William Macaulay
1   Department of Orthopedic Surgery, NYU Langone Health, New York, New York
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Venous thromboembolism (VTE) is a rare, but serious complication following total knee arthroplasty (TKA). Current VTE guidelines recommend pharmacologic agents with or without intermittent pneumatic compression devices (IPCDs). At our institution, both 81-mg aspirin (ASA) twice a day (BID) and portable IPCDs were previously prescribed to TKA patients at standard risk for VTE, but the IPCDs were discontinued and patients were treated with ASA alone going forward. The aim of this study is to determine if discontinued use of outpatient IPCDs is safe and does not increase the rate of VTE or any other related complications in patients following TKA. A retrospective review of 2,219 consecutive TKA cases was conducted, identifying patients with VTE, bleeding complications, infection, and mortality within 90 days postoperatively. Patients were divided into two cohorts. Patients in cohort one received outpatient IPCDs for a period of 14 days (control), while those in cohort two did not (ASA alone). All study patients received inpatient IPCDs and were maintained on 81-mg ASA BID for 28 days. A posthoc power analysis was performed using a noninferiority margin of 0.25 (α = 0.05; power = 80%), which showed that our sample size was fully powered for noninferiority for our reported deep vein thrombosis (DVT) rates, but not for pulmonary embolism (PE) rates. A total of 867 controls and 1,352 patients treated with ASA alone were identified. Only two control patients were diagnosed with a PE (0.23%), while one patient in the ASA alone group had DVT (0.07%). There was no statistical difference between these rates (p = 0.33). Furthermore, no differences were found in bleeding complications (p = 0.12), infection (p = 0.97), or 90-day mortality rates (p = 0.42) between both groups. The discontinued use of outpatient portable IPCDs is noninferior to outpatient IPCD use for DVT prophylaxis. Our findings suggest that this protocol change may be safe and does not increase the rate of VTE in standard risk patients undergoing TKA while using 81-mg ASA BID.

Keywords

aspirin - venous thromboembolism prophylaxis - outpatient portable intermittent pneumatic compression devices - primary total knee arthroplasty


Publication History

Received: 12 July 2020

Accepted: 05 October 2020

Article published online:
25 November 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Johanson NA, Lachiewicz PF, Lieberman JR. et al. American Academy of Orthopaedic Surgeons Clinical Practice Guideline on. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Bone Joint Surg Am 2009; 91 (07) 1756-1757
    CrossrefPubMedGoogle Scholar
  • 2 Geerts WH, Pineo GF, Heit JA. et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. In: Chest. Vol 126. American College of Chest Physicians; 2004; 338S-400S DOI: 10.1378/chest.126.3_suppl.338S.
    CrossrefPubMedGoogle Scholar
  • 3 Shahi A, Chen AF, Tan TL, Maltenfort MG, Kucukdurmaz F, Parvizi J. The incidence and economic burden of in-hospital venous thromboembolism in the United States. J Arthroplasty 2017; 32 (04) 1063-1066
    CrossrefPubMedGoogle Scholar
  • 4 Ollendorf DA, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health Syst Pharm 2002; 59 (18) 1750-1754
    CrossrefPubMedGoogle Scholar
  • 5 Gesell MW, González Della Valle A, Bartolomé García S. et al. Safety and efficacy of multimodal thromboprophylaxis following total knee arthroplasty: a comparative study of preferential aspirin vs. routine coumadin chemoprophylaxis. J Arthroplasty 2013; 28 (04) 575-579
    CrossrefPubMedGoogle Scholar
  • 6 González Della Valle A, Serota A, Go G. et al. Venous thromboembolism is rare with a multimodal prophylaxis protocol after total hip arthroplasty. Clin Orthop Relat Res 2006; 444 (444) 146-153
    CrossrefPubMedGoogle Scholar
  • 7 Crawford DA, Andrews RL, Morris MJ, Hurst JM, Lombardi Jr AV, Berend KR. Ambulatory portable pneumatic compression device as part of a multimodal aspirin-based approach in prevention of venous thromboembolism in outpatient total knee arthroplasty. Arthroplast Today 2020; 6 (03) 378-380
    CrossrefPubMedGoogle Scholar
  • 8 Budhiparama NC, Abdel MP, Ifran NN, Parratte S. Venous thromboembolism (VTE) prophylaxis for hip and knee arthroplasty: Changing trends. In: Current Reviews in Musculoskeletal Medicine. Vol 7. Humana Press Inc.; 2014: 108-116 DOI: 10.1007/s12178-014-9207-1
    CrossrefGoogle Scholar
  • 9 An VVG, Phan K, Levy YD, Bruce WJM. Aspirin as thromboprophylaxis in hip and knee arthroplasty: a systematic review and meta-analysis. J Arthroplasty 2016; 31 (11) 2608-2616
    CrossrefPubMedGoogle Scholar
  • 10 Falck-Ytter Y, Francis CW, Johanson NA. et al. Prevention of VTE in orthopedic surgery patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (02) e278S-e325S DOI: 10.1378/chest.11-2404.
    Google Scholar
  • 11 Flevas DA, Megaloikonomos PD, Dimopoulos L, Mitsiokapa E, Koulouvaris P, Mavrogenis AF. Thromboembolism prophylaxis in orthopaedics: an update. EFORT Open Rev 2018; 3 (04) 136-148
    Google Scholar
  • 12 Parvizi J, Huang R, Restrepo C. et al. Low-dose aspirin is effective chemoprophylaxis against clinically important venous thromboembolism following total joint arthroplasty a preliminary analysis. J Bone Joint Surg Am 2017; 99 (02) 91-98
    CrossrefPubMedGoogle Scholar
  • 13 Huang RC, Parvizi J, Hozack WJ, Chen AF, Austin MS. Aspirin is as effective as and safer than warfarin for patients at higher risk of venous thromboembolism undergoing total joint arthroplasty. J Arthroplasty 2016; 31 (09) 83-86
    CrossrefPubMedGoogle Scholar
  • 14 Azboy I, Barrack R, Thomas AM, Haddad FS, Parvizi J. Aspirin and the prevention of venous thromboembolism following total joint arthroplasty: commonly asked questions. Bone Joint J 2017; 99-B (11) 1420-1430
    CrossrefPubMedGoogle Scholar
  • 15 Feldstein MJ, Low SL, Chen AF, Woodward LA, Hozack WJ. A comparison of two dosing regimens of ASA following total hip and knee arthroplasties. J Arthroplasty 2017; 32 (9S): S157-S161
    CrossrefPubMedGoogle Scholar
  • 16 Schousboe JT, Brown GA. Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty. J Bone Joint Surg Am 2013; 95 (14) 1256-1264
    CrossrefPubMedGoogle Scholar
  • 17 Sarasin FP, Bounameaux H. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis. Thromb Haemost 2002; 87 (04) 586-592
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Pavon JM, Adam SS, Razouki ZA. et al. Effectiveness of intermittent pneumatic compression devices for venous thromboembolism prophylaxis in high-risk surgical patients: a systematic review. J Arthroplasty 2016; 31 (02) 524-532
    CrossrefPubMedGoogle Scholar
  • 19 Snyder MA, Sympson AN, Scheuerman CM, Gregg JL, Hussain LR. Efficacy in deep vein thrombosis prevention with extended mechanical compression device therapy and prophylactic aspirin following total knee arthroplasty: a randomized control trial. J Arthroplasty 2017; 32 (05) 1478-1482
    CrossrefPubMedGoogle Scholar
  • 20 Dietz MJ, Ray JJ, Witten BG, Frye BM, Klein AE, Lindsey BA. Portable compression devices in total joint arthroplasty: poor outpatient compliance. Arthroplast Today 2020; 6 (01) 118-122
    CrossrefPubMedGoogle Scholar
  • 21 Yeroushalmi D, Padilla J, Slover J, Schwarzkopf R, Macaulay W. Patient satisfaction and risk of falls with the use of intermittent pneumatic compression devices following total joint arthroplasty. Bull NYU Hosp Jt Dis 2020
    Google Scholar
  • 22 Arsoy D, Giori NJ, Woolson ST. Mobile compression reduces bleeding-related readmissions and wound complications after THA and TKA. Clin Orthop Relat Res 2018; 476 (02) 381-387
    CrossrefPubMedGoogle Scholar
  • 23 Colwell Jr CW, Froimson MI, Anseth SD. et al. A mobile compression device for thrombosis prevention in hip and knee arthroplasty. J Bone Joint Surg Am 2014; 96 (03) 177-183
    CrossrefPubMedGoogle Scholar
  • 24 Parvizi J, Ceylan HH, Kucukdurmaz F, Merli G, Tuncay I, Beverland D. Venous thromboembolism following hip and knee arthroplasty. J Bone Joint Surg Am 2017; 99 (11) 961-972
    CrossrefPubMedGoogle Scholar
  • 25 Mont MA, Jacobs JJ, Boggio LNAAOS. et al; Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg 2011; 19 (12) 768-776
    CrossrefPubMedGoogle Scholar
  • 26 Froimson MI, Murray TG, Fazekas AF. Venous thromboembolic disease reduction with a portable pneumatic compression device. J Arthroplasty 2009; 24 (02) 310-316
    CrossrefPubMedGoogle Scholar
  • 27 Bala A, Huddleston III JI, Goodman SB, Maloney WJ, Amanatullah DF. Venous thromboembolism prophylaxis after TKA: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?. Clin Orthop Relat Res 2017; 475 (09) 2205-2213
    CrossrefPubMedGoogle Scholar
  • 28 Borgdorff P, Tangelder GJ. Arguments favoring low versus high dose aspirin in the prophylaxis of venous thromboembolism. Thromb Res 2016; 139: 121-124
    CrossrefPubMedGoogle Scholar
  • 29 Faour M, Piuzzi NS, Brigati DP. et al. Low-dose aspirin is safe and effective for venous thromboembolism prophylaxis following total knee arthroplasty. J Arthroplasty 2018; 33 (7S): S131-S135
    CrossrefPubMedGoogle Scholar
  • 30 Mostafavi Tabatabaee R, Rasouli MR, Maltenfort MG, Parvizi J. Cost-effective prophylaxis against venous thromboembolism after total joint arthroplasty: warfarin versus aspirin. J Arthroplasty 2015; 30 (02) 159-164
    CrossrefPubMedGoogle Scholar
  • 31 Sharrock NE, Gonzalez Della Valle A, Go G, Lyman S, Salvati EA. Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res 2008; 466 (03) 714-721
    CrossrefPubMedGoogle Scholar